ReviewFoods (Basel, Switzerland)2021
Toxicological Evaluation of Piceatannol, Pterostilbene, and ε-Viniferin for Their Potential Use in the Food Industry: A Review.
Review in Foods (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 30 citations in OpenAlex.
- Piceatannol from Passion Fruit Seed Waste: A Circular Bioeconomy-Driven Pathway Toward a Skin-Targeted Bioactive.International journal of molecular sciences · 2026Review
- Natural Compounds TargetingNutrients · 2025Review
- Improved Bioavailability of Stilbenes fromMolecules (Basel, Switzerland) · 2025Article
- Potential Using of Resveratrol and Its Derivatives in Medicine.The Eurasian journal of medicine · 2024Article
- Metabolomics and quantitative analysis to determine differences in the geographical origins and species of Chinese dragon's blood.Frontiers in plant science · 2024Article
- Predicting phase-I metabolism of piceatannol: an in silico study.In silico pharmacology · 2024Article
- A novel approach to control Botrytis cinerea fungal infections: uptake and biological activity of antifungals encapsulated in nanoparticle based vectors.Scientific reports · 2022Article
- A Study on the Time-Effect and Dose-Effect Relationships of Polysaccharide fromFoods (Basel, Switzerland) · 2022Article
- In the shadow of resveratrol: biological activities of epsilon-viniferin.Journal of physiology and biochemistry · 2022Review
- Role of Bioactive Compounds in Obesity: Metabolic Mechanism Focused on Inflammation.Foods (Basel, Switzerland) · 2022Review
- Pterostilbene Increases LDL Metabolism in HL-1 Cardiomyocytes by Modulating the PCSK9/HNF1α/SREBP2/LDLR Signaling Cascade, Upregulating Epigenetic hsa-miR-335 and hsa-miR-6825, and LDL Receptor Expression.Antioxidants (Basel, Switzerland) · 2021Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The application of stilbenes in the food industry is being considered because of their biological activities. Piceatannol, pterostilbene and ε-viniferin have awakened the industry's interest. However, before they can be commercialized, we must first guarantee their safety for consumers. The present work reviews the toxicological studies performed with these stilbenes. A wide variety of studies has demonstrated their cytotoxic effects in both cancer and non-cancerous cell lines. In contrast, although DNA damage was detected by some authors, in vitro genotoxic studies on the effects of piceatannol, pterostilbene, and ε-viniferin remain scarce. None of the three reviewed substances have been evaluated using the in vitro tests required by the European Food Safety Authority (EFSA) as the first step in genotoxicity testing. We did not find any study on the toxic effects of these stilbenes in vivo. Thus, more studies are needed to confirm their safe use before they can be authorized as additive in the food industry.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.